GlassScriptPhysician profile
Keith H Fiman
NPI 1578564506
$11,440.74
in general payments reported to CMS, 2019-2025
39 companies · $29.54 in 2025
The $29.54 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,365 · 2020: $625 · 2021: $2,047 · 2022: $2,097 · 2023: $3,424 · 2024: $1,854 · 2025: $29.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,307.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,133.85 | 2019-2024 | |
| Janssen Biotech, INC. | $1,663.88 | 2019-2024 | Stelara, Remicade, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,652.27 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $819.41 | 2019-2024 | |
| Celgene Corporation | $761.93 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $674.97 | 2019-2024 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $589.60 | 2019-2024 | Stelara, Tremfya, Remicade |
| Merck Sharp & Dohme LLC | $360.68 | 2019-2024 | Dificid |
| Johnson & Johnson Health Care Systems INC. | $354.14 | 2023-2024 | Tremfya, Stelara, Darzalex |
| Redhill Biopharma INC. | $315.86 | 2020-2022 | |
| Amgen INC. | $279.89 | 2021-2023 | Amjevita, Avsola |
| Nestle Healthcare Nutrition INC. | $252.50 | 2021-2023 | |
| Lilly USA, LLC | $167.07 | 2023-2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $164.59 | 2019-2023 | Rebyota, Clenpiq |
| Ardelyx, INC. | $145.45 | 2023 | Ibsrela |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$59,349.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Fiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.